Medincell SA (PA:MEDCL) — Market Cap & Net Worth
Market Cap & Net Worth: Medincell SA (MEDCL)
Medincell SA (PA:MEDCL) has a market capitalization of $941.48 Million (€805.30 Million) as of June 17, 2026. Listed on the PA stock exchange, this France-based company holds position #9364 globally and #149 in its home market, demonstrating a -0.14% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Medincell SA's stock price €28.02 by its total outstanding shares 35906795 (35.91 Million). Review debt load of Medincell SA to assess the company's total debt and financial obligations.
Medincell SA Market Cap History: 2018 to 2026
Medincell SA's market capitalization history from 2018 to 2026. Data shows growth from $279.16 Million to $1.18 Billion (19.00% CAGR).
Index Memberships
Medincell SA is a constituent of 6 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
CAC Mid & Small
CACMS
|
$235.19 Billion | 0.40% | #57 of 119 |
|
CAC Small90
CACS
|
$36.74 Billion | 2.56% | #13 of 64 |
|
CAC All-Tradable
CACT
|
$2.89 Trillion | 0.03% | #115 of 179 |
|
CAC All-Tradable Net Total Return
CACTN
|
$2.89 Trillion | 0.03% | #115 of 179 |
|
CAC All Tradable Gross Total Return
CACTR
|
$2.89 Trillion | 0.03% | #115 of 179 |
|
CAC Health Care
FRHC
|
$260.58 Billion | 0.36% | #13 of 36 |
Weight: Medincell SA's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Medincell SA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Medincell SA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
41.42x
Medincell SA's market cap is 41.42 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $279.16 Million | $6.44 Million | -$9.57 Million | 43.36x | N/A |
| 2019 | $288.81 Million | $1.44 Million | -$19.69 Million | 200.15x | N/A |
| 2020 | $428.18 Million | $2.85 Million | -$23.91 Million | 150.13x | N/A |
| 2021 | $419.79 Million | $8.19 Million | -$19.02 Million | 51.28x | N/A |
| 2022 | $259.43 Million | $4.09 Million | -$24.81 Million | 63.43x | N/A |
| 2023 | $302.25 Million | $9.94 Million | -$32.01 Million | 30.39x | N/A |
| 2024 | $697.69 Million | $9.16 Million | -$25.04 Million | 76.17x | N/A |
| 2025 | $1.06 Billion | $25.54 Million | -$18.44 Million | 41.42x | N/A |
Competitor Companies of MEDCL by Market Capitalization
Companies near Medincell SA in the global market cap rankings as of June 17, 2026.
Key companies related to Medincell SA by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #442 globally with a market cap of $63.33 Billion USD.
- UCB SA (BR:UCB): Ranked #550 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $453.17 |
| #442 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.33 Billion | $614.73 |
| #550 | UCB SA | BR:UCB | $49.68 Billion | €250.00 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €755.80 |
Medincell SA Historical Marketcap From 2018 to 2026
Between 2018 and today, Medincell SA's market cap moved from $279.16 Million to $ 1.18 Billion, with a yearly change of 19.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €1.18 Billion | +11.19% |
| 2025 | €1.06 Billion | +51.62% |
| 2024 | €697.69 Million | +130.83% |
| 2023 | €302.25 Million | +16.50% |
| 2022 | €259.43 Million | -38.20% |
| 2021 | €419.79 Million | -1.96% |
| 2020 | €428.18 Million | +48.26% |
| 2019 | €288.81 Million | +3.46% |
| 2018 | €279.16 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Medincell SA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $941.48 Million USD |
| MoneyControl | $941.48 Million USD |
| MarketWatch | $941.48 Million USD |
| marketcap.company | $941.48 Million USD |
| Reuters | $941.48 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Medincell SA
MedinCell S.A., a clinical-stage and commercial biopharmaceutical licensing company, develops long acting injectables in various therapeutic areas in France. The company develops solutions based on BEPO, a long-acting injectable technology. It offers UZEDY (mdc-IRM) for the treatment of schizophrenia in adults and bipolar I disorder. It is also developing mdc-TJK, a subcutaneous injection that is… Read more